Indian J Pharm Close
 

Figure 5: Effect of PECB pretreatment on scopolamine-induced amnesia on acetylcholinesterase, NF-κB, Tau Nrf2, HO-1, and PP2A mRNA expression in the hippocampus of rats. (a) Lane 1: DNA marker, lane 2: normal control, lane 3: scopolamine, lane 4: tacrine + scopolamine, lane 5: PECB (50 mg/kg) + scopolamine, lane 6: PECB (100 mg/kg) + scopolamine, lane 7: PECB (200 mg/kg) + scopolamine. Quantitative data expression of (b) acetylcholinesterase, (c) NF-κB, (d) Tau, (e) Nrf2, (f) HO-1, and (g) PP2A. **P < 0.01, ***P < 0.001 compared with normal control group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with scopolamine-treated group

Figure 5: Effect of PECB pretreatment on scopolamine-induced amnesia on acetylcholinesterase, NF-κB, Tau Nrf2, HO-1, and PP2A mRNA expression in the hippocampus of rats. (a) Lane 1: DNA marker, lane 2: normal control, lane 3: scopolamine, lane 4: tacrine + scopolamine, lane 5: PECB (50 mg/kg) + scopolamine, lane 6: PECB (100 mg/kg) + scopolamine, lane 7: PECB (200 mg/kg) + scopolamine. Quantitative data expression of (b) acetylcholinesterase, (c) NF-κB, (d) Tau, (e) Nrf2, (f) HO-1, and (g) PP2A. **<i>P</i> < 0.01, ***<i>P</i> < 0.001 compared with normal control group; #<i>P</i> < 0.05, ##<i>P</i> < 0.01, ###<i>P</i> < 0.001 compared with scopolamine-treated group